National Institutes of Health

Former FDA official Tim Cote joins Emmaus Medical as regulatory advisor

Friday, May 10, 2013 08:00 AM

Emmaus Medical, a specialty pharmaceutical and regenerative medicine company, has appointed Timothy Cote, M.D., MPH, former director of the Office of Orphan Product Development of the FDA, as its regulatory advisor. Cote will advise Emmaus on the regulatory pathway for the company's sickle cell disease treatment.

More... »

Lonza awarded NIH contract for research grade iPSCs

Monday, February 25, 2013 09:59 AM

The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza’s Walkersville, Md., facility a contract to generate induced pluripotent stem cells (iPSCs) for research purposes.  The contract is a three year agreement with a value up to $6.9 million dollars.                                      

More... »

NIH funds research to identify Parkinson's biomarkers

Wednesday, February 20, 2013 03:46 PM

The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), awarded a three-year, $900,000 grant to the Center for Biomedical Imaging Statistics at Emory's Rollins School of Public Health. The grant will fund the center's biomarker research in Parkinson's disease to identify non-invasive imaging measures that can detect changes in brain function and biochemistry.

More... »

Lentigen receives Orphan Drug status for gene therapy for glioblastoma multiforme

Thursday, February 14, 2013 08:00 AM

Lentigen, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced that that the FDA has granted orphan drug status to LG631-CD34, P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells, for bone marrow protection in the treatment of glioblastoma multiforme.

More... »

FDA offers new guidance on developing drugs for Alzheimer's

Friday, February 8, 2013 11:47 AM

The FDA has issued a proposal designed to assist companies developing new treatments for patients in the early stages of Alzheimer's disease, before the onset of noticeable dementia.

More... »

Factor Bioscience awarded two NIH grants for Alzheimer's research

Monday, November 19, 2012 11:12 AM

The National Institutes of Health, through the National Center for Advancing Translational Sciences, has awarded Factor Bioscience, a developer of cell-based therapeutics and research tools, two Small Business Innovation Research (SBIR) grants to accelerate the development of new treatments for Alzheimer's disease.

More... »

Investigational drugs chosen for major Alzheimer's prevention trial

Thursday, October 11, 2012 07:00 AM

Scientists have selected the first investigational drugs for a worldwide Alzheimer's disease prevention trial. The pioneering study, expected to start by early 2013, initially will test three promising drugs—gantenerumab, solanezumab and an unnamed BACE inhibitor—each designed to target Alzheimer's in different ways.

More... »

Risk gene for Alzheimer's disease associated with lower brain amyloid

Thursday, October 4, 2012 12:57 PM

Researchers investigating a known gene risk factor for Alzheimer's disease discovered it is associated with lower levels of beta amyloid—a brain protein involved in Alzheimer's—in cognitively healthy older people.

More... »

Transgenomic awarded NIH STTR grant for pancreatic cancer research

Thursday, August 23, 2012 11:15 AM

Transgenomic,an Omaha, Neb.-based global biotechnology company focused on personalized medicine, has been awarded a $100,000 Small Business Technology Transfer Program (STTR) phase I grant by the National Institutes of Health’s National Center For Advancing Translational Sciences.

More... »

Thirty teams compete to interpret three families' genomes

Monday, August 20, 2012 12:08 PM

In a contest led by Boston Children's Hospital, 30 teams from around the world are vying to interpret the DNA sequences of three children with rare conditions whose cause remains a mystery—with the goal of establishing "best practices" for interpreting genomic data.

More... »